Evaluation of the susceptibility of pathogenicCandida species to fluconazole
- 41 Downloads
A fluconazole 25 ug disk diffusion test was used to test 2230 consecutively isolatedCandida strains from 42 different hospital laboratories in 23 countries. Ninety seven percent of 1634Candida albicans isolates and 83.4% of 596 non-Candida albicans isolates were susceptible to fluconazole, applying the proposed breakpoints (≥26 mm for susceptible strains and 18–25 mm for dosedependent susceptible strains). This is the first hospital laboratory study to evaluate a large number and wide range of sequentialCandida isolates from patients with all types of hospital infections. The fluconazole disk diffusion test appears to be a low-cost, reproducible, and accurate means of assessing the in vitro susceptibility ofCandida isolates.
KeywordsInternal Medicine Laboratory Study Fluconazole Disk Diffusion Susceptible Strain
Unable to display preview. Download preview PDF.
- 1.National Committee for Clinical Laboratory Standards: Reference method for broth dilution antifungal susceptibility testing of yeast. Tentative standard M27-T. NCCLS, Villanova, PA, 1995.Google Scholar
- 5.Espinel-Ingroff A, Rodriguez-Tudela JL, Martinez-Suarez JV: Comparison of two microdilution procedures with the proposed NCCLS reference macro-dilution method M27-P for in vitro testing of fluconazole resistant and susceptible isolates ofCandida albicans. Journal of Clinical Microbiology 1995, 33: 3154–3158.PubMedGoogle Scholar
- 6.Colombo J, Barchiesi F, McGough DA, Fotherfill AW, Rinaldi MG: Evaluation of the E-test system versus a microtitre broth method for antifungal susceptibility testing of yeast against fluconazole and itraconazole. Antimicrobial Agents and Chemotherapy 1995, 36: 93–100.Google Scholar
- 7.Troillet N, Durussel C, Bille J, Glauser MR Chave JP: Correlation between in vitro susceptibility ofCandida albicans and fluconazole resistant oropharyngeal candidiasis in HIV-infected patients. European Journal of Clinical Microbiology & Infectious Diseases 1993, 12: 911–915.Google Scholar
- 9.Rex J, Pfaller MA, Barry AL, Nelson PW, Webb CD: Antifungal susceptibility testing of isolates from a randomized multicenter trial of fluconazole versus amphotericin B as treatment of non-neutropenic patients with candidemia. Antimicrobial Agents and Chemotherapy 1995, 39: 40–44.PubMedGoogle Scholar
- 10.van't Wout JW: Fluconazole treatment of candidal infections caused by non-albicans Candida species. European Journal of Clinical Microbiology & Infectious Diseases 1996, 15: 238–242.Google Scholar
- 12.Rex J, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, Lancaster M, Odds FC, Rinaldi MG, Walsh TJ, Barry A: Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro — in vivo correlation data for fluconazole, itraconazole, andCandida infections. Clinical Infectious Diseases 1997, 24: 235–247.PubMedGoogle Scholar